 |
|
The Magnitude and Challenge of False-Positive Newborn Screening Test Results
Charles Kwon, MD;
Philip M. Farrell, MD, PhD
Arch Pediatr Adolesc Med. 2000;154:714-718.
Objectives This study examined for the first time to our knowledge the national data available from newborn screening programs in the United States and determined the salient characteristics of various screening tests for 3 hereditary metabolic disorders and 2 congenital endocrinopathies with emphasis on positive predictive values (PPVs) to delineate the magnitude of false-positive results.
Methods Reports published by the Council of Regional Networks for Genetic Services for 1990 through 1994 were examined carefully, paying particular attention to phenylketonuria, galactosemia, biotinidase deficiency, congenital hypothyroidism, and congenital adrenal hyperplasia (CAH). Because of recent improvements in data collecting, reporting, and tabulating, we used data from 1993 and 1994 to determine the apparent sensitivity, specificity, relative incidence rates, and PPVs for the 5 disorders. For biotinidase deficiency and CAH, we also calculated relative incidence rates and PPVs for 1991 and 1992.
Results Our analyses revealed the following best estimates for the relative incidence rates of 5 disorders: phenylketonuria, 1:14,000; galactosemia, 1:59,000; biotinidase deficiency, 1:80,000; congenital hypothyroidism, 1:3300; and CAH, 1:20,000. An apparent sensitivity of 100% has been reported by the various states for most of the disorders, and specificity levels are all above 99%. The PPVs, however, range from 0.5% to 6.0%. Consequently, on average, there are more than 50 false-positive results for every true-positive result identified through newborn screening in the United States.
Conclusions The magnitude of false-positive results generated in newborn screening programs, particularly for congenital endocrinopathies, presents a great challenge for future improvement of this important public health program. Attention must be given to improved laboratory tests, use of more specific markers, and better risk communication for families of patients with false-positive test results.
From the Department of Pediatrics, University of Wisconsin Medical School, Madison.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Early Detection of Pompe Disease by Newborn Screening Is Feasible: Results From the Taiwan Screening Program
Chien et al.
Pediatrics 2008;122:e39-e45.
ABSTRACT
| FULL TEXT
Rapid 2nd-Tier Test for Measurement of 3-OH-Propionic and Methylmalonic Acids on Dried Blood Spots: Reducing the False-Positive Rate for Propionylcarnitine during Expanded Newborn Screening by Liquid Chromatography-Tandem Mass Spectrometry
la Marca et al.
Clin. Chem. 2007;53:1364-1369.
ABSTRACT
| FULL TEXT
HIV Screening and False-Positive Results--Reply
Gostin
JAMA 2007;297:948-948.
FULL TEXT
State Newborn Screening in the Tandem Mass Spectrometry Era: More Tests, More False-Positive Results
Tarini et al.
Pediatrics 2006;118:448-456.
ABSTRACT
| FULL TEXT
Newborn Screening Technology: Proceed With Caution
Botkin et al.
Pediatrics 2006;117:1793-1799.
FULL TEXT
Recommendations for Effective Newborn Screening Communication: Results of Focus Groups With Parents, Providers, and Experts
Davis et al.
Pediatrics 2006;117:S326-S340.
ABSTRACT
| FULL TEXT
Impact of Specific Medical Interventions on Reducing the Prevalence of Mental Retardation
Brosco et al.
Arch Pediatr Adolesc Med 2006;160:302-309.
ABSTRACT
| FULL TEXT
Content of Communication by Pediatric Residents After Newborn Genetic Screening
Farrell et al.
Pediatrics 2005;116:1492-1498.
ABSTRACT
| FULL TEXT
Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia
Votava et al.
Eur J Endocrinol 2005;152:869-874.
ABSTRACT
| FULL TEXT
Elevated Urine Pregnanetriolone Definitively Establishes the Diagnosis of Classical 21-Hydroxylase Deficiency in Term and Preterm Neonates
Homma et al.
J. Clin. Endocrinol. Metab. 2004;89:6087-6091.
ABSTRACT
| FULL TEXT
Improving Neonatal Screening for Congenital Adrenal Hyperplasia
Speiser
J. Clin. Endocrinol. Metab. 2004;89:3685-3686.
FULL TEXT
Steroid Profiling by Tandem Mass Spectrometry Improves the Positive Predictive Value of Newborn Screening for Congenital Adrenal Hyperplasia
Minutti et al.
J. Clin. Endocrinol. Metab. 2004;89:3687-3693.
ABSTRACT
| FULL TEXT
Expanded Newborn Screening for Inborn Errors of Metabolism by Electrospray Ionization-Tandem Mass Spectrometry: Results, Outcome, and Implications
Schulze et al.
Pediatrics 2003;111:1399-1406.
ABSTRACT
| FULL TEXT
Not as Pink as You Think!
Pass
Pediatrics 2003;111:670-671.
FULL TEXT
Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening
Schoen et al.
Pediatrics 2002;110:781-786.
ABSTRACT
| FULL TEXT
Tandem Mass Spectrometric Analysis for Amino, Organic, and Fatty Acid Disorders in Newborn Dried Blood Spots: A Two-Year Summary from the New England Newborn Screening Program
Zytkovicz et al.
Clin. Chem. 2001;47:1945-1955.
ABSTRACT
| FULL TEXT
Is Public Health Ready for Genetics? An Unanswered Question
Cunningham et al.
Arch Pediatr Adolesc Med 2001;155:1175-1176.
FULL TEXT
The Importance of Newborn Screening
Hinman; et al.
Pediatrics 2001;108:821-821.
ABSTRACT
| FULL TEXT
Early Diagnosis of Cystic Fibrosis
Grosse et al.
Pediatrics 2001;107:1492-1492.
FULL TEXT
Genetic Counseling and Risk Communication Services of Newborn Screening Programs
Farrell et al.
Arch Pediatr Adolesc Med 2001;155:120-126.
ABSTRACT
| FULL TEXT
|
